MedTrace Logo

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

NCT05177042 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-28

Study results available
· View outcomes & findings →

Summary

Phase 1b study to assess the combination of ARV-110 (bavdegalutamide) and abiraterone in participants with metastatic prostate cancer with rising PSA values on abiraterone.

Conditions

  • Prostate Cancer Metastatic

Interventions

DRUG

Bavdegalutamide

Bavdegalutamide oral tablets daily in 28 day cycles.

DRUG

Abiraterone

Abiraterone oral tablets daily at the same dose they were on prior to study enrollment with a concomitant corticosteroid of Investigator's choice as per local label/guidelines.

Sponsors & Collaborators

  • Arvinas Androgen Receptor, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-13
Primary Completion
2024-07-02
Completion
2025-04-10
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177042 on ClinicalTrials.gov